Brilliant Violet 605 anti-human CD357 GITR Antibody anti-CD357 - 108-17,BioLegend,371214

Host

Mouse

Reactivity

Human

Application

FC -Quality tested

Platform ID

BAB412358968

BioLegend

Headquarters

8999 BioLegend Way San Diego, CA 92121 United States

Contact

Tel: 1-858-455-9588
Fax: +49 (4131) 7023913

Email:

Product Specifications
Scientific Background

Specifications

NameBrilliant Violet 605 anti-human CD357 GITR Antibody anti-CD357 - 108-17
Cat. No.371214
HostMouse
RRIDAB_2687162 (BioLegend Cat. No. 371213)AB_2687163 (BioLegend Cat. No. 371214)
IsotypeMouse IgG2a, κ
ReactivityHuman
ApplicationFC -Quality tested
ClonalityMonoclonal
Clone Number108-17
ConcentrationLot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in ourCertificate of Analysisonline tool.)
TargetCD357
ImmunogenRecombinant human GITR-Fc chimera
PurityThe antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
FormulationPhosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
StorageThe antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light.Do not freeze.
Regulatory StatusResearch Use Only

Scientific Background

GITR (glucocorticoid-induced TNF receptor family-regulated gene) is a 25 kD TNF receptor superfamily member (also known as AITR and TNFRSF18). GITR is expressed on activated lymphocytes and is upregulated by T cell receptor engagement. The cytoplasmic domain of GITR is homologous to CD40, 4-1BB and CD27 and has been shown to interact with TRAF 1-3, but not TRAF 5 or 6. GITR signaling has been shown to regulate T cell proliferation and TCR-mediated apoptosis, and to break immunological self-tolerance. GITR binds GITRL and is involved in the development of regulatory T cells and to regulate the activity of Th1 subsets.

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.